<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925300</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_BCS_101</org_study_id>
    <nct_id>NCT01925300</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin</brief_title>
  <official_title>A Randomized, Open-label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Bisoprolol and Rosuvastatin in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designated to evaluate the pharmacokinetic interactions of bisoprolol and
      rosuvastatin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the drug-drug interactions of bisoprolol and rosuvastatin: Cmax,ss(Maximum steady-state plasma drug concentration during a dosage interval ), AUCτ(Area Under the Curve)</measure>
    <time_frame>6 days</time_frame>
    <description>Administration of Investigational Product : 6 days/period(total 3 period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the bisoprolol and rosuvastatin:tmax,ss(Time to reach Cmax,ss), t1/2, Cmin,ss(Minimum steady-state plasma drug concentration during a dosage interval ), CL/Fss(Oral Clearance), Vd/Fss(Apparent Volume of Distribution)</measure>
    <time_frame>6 days</time_frame>
    <description>Administration of Investigational Product : 6 days/period(total 3 period)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration : 6 days, per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration : 6 days, per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concor 5mg 2T and Crestor 20 mg 1Tab, qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination administration : 6 days, per oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab</intervention_name>
    <arm_group_label>Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab</intervention_name>
    <arm_group_label>Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concor 5mg 2T and Crestor 20 mg 1Tab</intervention_name>
    <arm_group_label>Concor 5mg 2T and Crestor 20 mg 1Tab, qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 55 years old(inclusive)

          -  Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)

          -  Medically healthy with no clinically significant vital signs (sitting position blood
             pressure, pulse rate) (90 mmHg ≤ systolic blood pressure ≤ 150 mmHg, 60 mmHg ≤
             diastolic blood pressure ≤ 100 mmHg, 50 beats per minute ≤ pulse rate ≤ 100 beats per
             minute)

          -  Available for the entire study period

          -  Understand the requirements of the study and voluntarily consent to participate in the
             study

        Exclusion Criteria:

          -  Subjects with a history of gastrointestinal diseases which might significantly change
             ADME(Absorption, Distribution, Metabolism and Excretion) of medicines

          -  History of clinically significant arrhythmic, peripheral vascular,thyroid,
             bronchospasm, asthma disease

          -  Subjects with anaphylaxis to bisoprolol and/or rosuvastatin

          -  History of drug abuse

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine(coffee,tea,coke) or grapefruit juice &gt; 4cups/day

               -  smoking &gt; 20 cigarettes/day

               -  alcohol &gt; 140g/week

          -  Clinical laboratory test values are outside the accepted normal range

               -  AST(Aspartate Transaminase), ALT(ALanine Transaminase)( &gt; 1.5 times to normal
                  range

               -  CK(Creatine Kinase) &gt; 1.5 times to normal range

               -  Estimated GFR(Glomerular Filtration Rate) &lt; 60 mL/min

          -  Subjects with whole blood donation within 60days, component blood donation within
             30days and blood transfusion within 30days prior to study medication dosing

          -  Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-wook Ko, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Conter</affiliation>
  </overall_official>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

